Form 4: Blueprint Medicines CEO Kate Haviland Sells Shares Under 10b5-1 Trading Plan

Blueprint Medicines CEO Kate Haviland sold a total of 2,353 shares of common stock on November 29, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Kate Haviland, CEO of Blueprint Medicines, sold 400 shares of common stock at an average price of $95.40 on November 29, 2024.
• She also sold 1,746 shares at an average price of $96.74 and 207 shares at an average price of $97.76 on the same day.
• These transactions were executed under a pre-arranged trading plan adopted on August 30, 2024, in accordance with Rule 10b5-1.
• Following these sales, Ms. Haviland beneficially owns 150,824 shares of Blueprint Medicines common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although these sales were pre-planned.

Industry Context

Executive stock sales are a common occurrence, especially under pre-arranged trading plans like 10b5-1, which are designed to avoid accusations of insider trading. This is a routine filing and does not indicate any change in the company's outlook.

Comparison to Industry Standards

• Many executives at publicly traded companies use 10b5-1 trading plans to manage their personal finances and avoid insider trading accusations.
• The volume of shares sold is relatively small compared to the total outstanding shares of Blueprint Medicines, suggesting this is a routine transaction.
• Comparable companies in the biotech sector often see similar filings from their executives.

Stakeholder Impact

• The stock sales may have a minor impact on the share price, but the pre-planned nature of the transactions should mitigate any significant negative reaction.

Key Dates

Keywords

Blueprint Medicines, Kate Haviland, stock sale, insider trading, Form 4, 10b5-1 plan, executive compensation